Keryx Biopharmaceuticals (NASDAQ:KERX) reported Q4 2017 earnings this Morning, coming in at ($0.26) per share, missing Wall Street’s estimates of ($0.18) per Share. Revenue for the quarter came in at $18.70 million beating analyst estimates of $17.53 million Recent Insider Trading for Keryx Biopharmaceuticals (NASDAQ:KERX)
- On 1/29/2018 Brian Adams, General Counsel, sold 1,541 with an average share price of $4.81 per share and the total transaction amounting to $7,412.21.
- On 1/29/2018 Scott A. Holmes, CFO, sold 2,830 with an average share price of $4.81 per share and the total transaction amounting to $13,612.30.
- On 1/23/2018 John F. Neylan, Insider, sold 1,322 with an average share price of $4.92 per share and the total transaction amounting to $6,504.24.
- On 1/18/2018 Christine A. Carberry, COO, sold 9,048 with an average share price of $4.87 per share and the total transaction amounting to $44,063.76.
- On 1/5/2018 Brian Adams, General Counsel, sold 753 with an average share price of $4.69 per share and the total transaction amounting to $3,531.57.
- On 1/5/2018 Greg Madison, CEO, sold 1,067 with an average share price of $4.69 per share and the total transaction amounting to $5,004.23.
Recent Trading for Keryx Biopharmaceuticals (NASDAQ:KERX) Shares of Keryx Biopharmaceuticals closed the previous trading session at 4.44 down -0.19 4.10% with 4.460000038146973 shares trading hands.